Co-administration of Shingles and RSV Vaccines Produces Positive …
WEB1 day ago · GSK plc recently announced topline Phase 3 clinical trial data for a combination regimen of two of its vaccines: the RSV vaccine Arexvy and Shingrix, a market-leading shingles shot. While GSK did not provide specific clinical trial (NCT05966090) data in its September 18, 2024 announcement, the company did confirm that co-administering Arexvy with Shingrix resulted in a “non-inferior immune ...
GSK Builds Combo Case for RSV, Shingles Shots With Phase III Data
WEB1 day ago · GSK will use these Phase III data to build a regulatory case for the co-administration of Arexvy with Shingrix, which, if approved, could help the company shore up sales for these products. The company plans to file submissions with the FDA and the European Medicines Agency, according to the announcement. Arexvy is …
GSK Announces Positive Topline Data on Co-Administration of …
WEB2 days ago · Indication for SHINGRIX SHINGRIX is an FDA-approved vaccine for the prevention of shingles (herpes zoster) in: Adults 50 years and older. Adults 18 years and older who are or will be at increased ...
GSK Announces Positive Topline Data on Co-Administration of
WEB2 days ago · About SHINGRIX (Recombinant Zoster Vaccine or RZV) SHINGRIX is a non-live, recombinant subunit vaccine indicated for the prevention of shingles in adults 50 and over. It combines an antigen, glycoprotein E, ... BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect ...
Shingles vaccines may reduce dementia risk, two large new studies ... - CNN
WEBJul 30, 2024 · CNN — Two new studies suggest that getting a vaccine to protect against a painful case of shingles may be beneficial for memory, too. An estimated 98% of US adults have had chickenpox and are at...
New shingles vaccine could reduce risk of dementia
WEBJul 25, 2024 · The new recombinant shingles vaccine ‘Shingrix’ is associated with a reduced risk of dementia compared to an earlier shingles vaccine, according to a major new study published in Nature Medicine. It is also …
Large study of shingles vaccine finds strong effectiveness over 4 …
WEBJan 8, 2024 · Shingrix is a vaccine that uses recombinant technology and has been the recommended shingles vaccine in the U.S. since 2017 for people aged 50 and older. In 2021, the CDC Advisory Committee on Immunization Practices voted to recommend Shingrix to immunocompromised people ages 19 years or older.
Two-dose shingles vaccine is still highly effective after four years
WEBApr 1, 2024 · The CDC recommends adults ages 50 and older get two doses of the recombinant zoster vaccine (Shingrix), with the doses separated by two to six months, to prevent shingles. But how long can it offer protection?
New long-term data show SHINGRIX continues to provide high
WEBApr 17, 2024 · GSK plc (LSE/NYSE: GSK) today announced positive data from the ZOSTER-049 long-term follow-up phase III trial which followed participants for up to approximately 11 years following initial vaccination with SHINGRIX (Recombinant Zoster Vaccine or RZV).
Pfizer and BioNTech Initiate Phase 1/2 Study of First mRNA-based ...
WEBFeb 10, 2023 · NEW YORK and MAINZ, GERMANY, FEBRUARY 10, 2023 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the start of a Phase 1/2 trial exploring the safety, tolerability, and immunogenicity of the companies’ mRNA vaccine candidates against shingles (also known as herpes zoster, or HZ), a debilitating disease caused by the varicel...